These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30832611)

  • 21. Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children.
    Sugaya N; Tamura D; Yamazaki M; Ichikawa M; Kawakami C; Kawaoka Y; Mitamura K
    Clin Infect Dis; 2008 Aug; 47(3):339-45. PubMed ID: 18582202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the effectiveness of Zanamivir and Oseltamivir against influenza A/H1N1, A/H3N2, and B.
    Kawai N; Ikematsu H; Iwaki N; Maeda T; Kawashima T; Hirotsu N; Kashiwagi S
    Clin Infect Dis; 2009 Apr; 48(7):996-7. PubMed ID: 19260819
    [No Abstract]   [Full Text] [Related]  

  • 23. Quantitative analysis of influenza A (H3N2) E119V and R292K variants in clinical specimens by real-time reverse transcription polymerase chain reaction.
    Sato M; Honzumi K; Sato T; Hashimoto K; Watanabe M; Miyazaki K; Kawasaki Y; Hosoya M
    J Clin Virol; 2015 Jul; 68():97-103. PubMed ID: 26071346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic characterization of circulating seasonal Influenza A viruses (2005-2009) revealed introduction of oseltamivir resistant H1N1 strains during 2009 in eastern India.
    Agrawal AS; Sarkar M; Ghosh S; Roy T; Chakrabarti S; Lal R; Mishra AC; Chadha MS; Chawla-Sarkar M
    Infect Genet Evol; 2010 Dec; 10(8):1188-98. PubMed ID: 20678590
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial.
    Fry AM; Goswami D; Nahar K; Sharmin AT; Rahman M; Gubareva L; Azim T; Bresee J; Luby SP; Brooks WA
    Lancet Infect Dis; 2014 Feb; 14(2):109-18. PubMed ID: 24268590
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of Neuropsychiatric Adverse Events in Patients Treated with Oseltamivir in Spontaneous Adverse Event Reports.
    Ueda N; Umetsu R; Abe J; Kato Y; Nakayama Y; Kato Z; Kinosada Y; Nakamura M
    Biol Pharm Bull; 2015; 38(10):1638-44. PubMed ID: 26424023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Post-marketing assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: an updated review.
    Toovey S; Prinssen EP; Rayner CR; Thakrar BT; Dutkowski R; Koerner A; Chu T; Sirzen-Zelenskaya A; Britschgi M; Bansod S; Donner B
    Adv Ther; 2012 Oct; 29(10):826-48. PubMed ID: 23054689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the efficacies of amantadine treatment of swine-origin influenza virus A H1N1 and seasonal influenza H1N1 and H3N2 in Japan (2008-2009).
    Miyachi K; Watanabe A; Iida H; Hattori H; Ukai H; Takano T; Hankins RW
    J Infect Chemother; 2011 Aug; 17(4):524-9. PubMed ID: 21360013
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized, controlled trial comparing traditional herbal medicine and neuraminidase inhibitors in the treatment of seasonal influenza.
    Nabeshima S; Kashiwagi K; Ajisaka K; Masui S; Takeoka H; Ikematsu H; Kashiwagi S
    J Infect Chemother; 2012 Aug; 18(4):534-43. PubMed ID: 22350323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial.
    Wang C; Cao B; Liu QQ; Zou ZQ; Liang ZA; Gu L; Dong JP; Liang LR; Li XW; Hu K; He XS; Sun YH; An Y; Yang T; Cao ZX; Guo YM; Wen XM; Wang YG; Liu YL; Jiang LD
    Ann Intern Med; 2011 Aug; 155(4):217-25. PubMed ID: 21844547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The association between oseltamivir use and adverse neuropsychiatric outcomes among TRICARE beneficiaries, ages 1 through 21 years diagnosed with influenza.
    Casscells SW; Granger E; Kress AM; Linton A
    Int J Adolesc Med Health; 2009; 21(1):79-89. PubMed ID: 19526698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exertional rhabdomyolysis after influenza A (H3N2) infection in a basketball player boy.
    Sevketoglu E; Kural B; Beskardes AE; Hatipoglu S
    Ann Trop Paediatr; 2011; 31(1):93-6. PubMed ID: 21262116
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emergence of oseltamivir-resistant influenza A/H3N2 virus with altered hemagglutination pattern in a hematopoietic stem cell transplant recipient.
    Cohen-Daniel L; Zakay-Rones Z; Resnick IB; Shapira MY; Dorozhko M; Mador N; Greenbaum E; Wolf DG
    J Clin Virol; 2009 Feb; 44(2):138-40. PubMed ID: 19157971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ["Oseltamivir-induced delirium"].
    Kruker AT; Krause M
    Ther Umsch; 2010 Dec; 67(12):613-5. PubMed ID: 21108186
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is oseltamivir (Tamiflu) safe? Re-examining the Tamiflu 'ado' from Japan.
    Okamoto E
    Expert Rev Pharmacoecon Outcomes Res; 2010 Feb; 10(1):17-24. PubMed ID: 20121561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children.
    Sugaya N; Mitamura K; Yamazaki M; Tamura D; Ichikawa M; Kimura K; Kawakami C; Kiso M; Ito M; Hatakeyama S; Kawaoka Y
    Clin Infect Dis; 2007 Jan; 44(2):197-202. PubMed ID: 17173216
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimum timing of oseltamivir: lessons from Bangladesh.
    Ison MG
    Lancet Infect Dis; 2014 Feb; 14(2):88-9. PubMed ID: 24268592
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons.
    Kawai N; Ikematsu H; Hirotsu N; Maeda T; Kawashima T; Tanaka O; Yamauchi S; Kawamura K; Matsuura S; Nishimura M; Iwaki N; Kashiwagi S
    Clin Infect Dis; 2009 Dec; 49(12):1828-35. PubMed ID: 19911968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Longer virus shedding in influenza B than in influenza A among outpatients treated with oseltamivir.
    Kawai N; Ikematsu H; Iwaki N; Kawashima T; Maeda T; Mitsuoka S; Kondou K; Satoh I; Miyachi K; Yamaga S; Shigematsu T; Hirotsu N; Kashiwagi S
    J Infect; 2007 Sep; 55(3):267-72. PubMed ID: 17604839
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A/H1N1 pandemic. Oseltamivir's adverse events.
    Strong M; Burrows J; Redgrave P
    BMJ; 2009 Aug; 339():b3249. PubMed ID: 19671604
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.